DOCSHealthcare · Health Information ServicesThe 21 Wall Street analysts covering Doximity, Inc. hold a median 12-month price target of $28 — +10.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Doximity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (93): The business earns solid, repeatable profits on what it owns.
Momentum (8): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DOCS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +10.6% from it.
Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Truist Securities | Maintains | Hold | $19 → $24 |
| 10 Aug 2026 | Wells Fargo | Downgrade | Underweight | $18 |
| 7 Aug 2026 | Evercore ISI Group | Maintains | In-Line | $22 → $40 |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | $26 → $31 |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | $42 → $47 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | $38 → $20 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | — |
| 15 May 2026 | Barclays | Downgrade | Equal-Weight | — |
| 15 May 2026 | Goldman Sachs | Maintains | Neutral | — |
| 14 May 2026 | Baird | Downgrade | Neutral | — |
| 14 May 2026 | BMO Capital | Maintains | Market Perform | — |
| 14 May 2026 | BTIG | Downgrade | Neutral | — |
| 14 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 14 May 2026 | Goldman Sachs | Maintains | Neutral | — |
| 14 May 2026 | Jefferies | Downgrade | Hold | — |
| 14 May 2026 | JP Morgan | Maintains | Neutral | — |
| 14 May 2026 | Keybanc | Downgrade | Sector Weight | — |
| 14 May 2026 | Leerink Partners | Maintains | Outperform | — |
| 14 May 2026 | Mizuho | Maintains | Neutral | — |
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DOCS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 27% of US stocks
Cheaper than 19% of US stocks
Cheaper than 22% of US stocks
Cheaper than 17% of US stocks
Higher than 45% of US stocks
Higher than 9% of US stocks
Higher than 94% of US stocks
Higher than 81% of US stocks
Higher than 86% of US stocks
Higher than 78% of US stocks
Higher than 93% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Doximity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A Doximity director, Cabral, sold 7,500 shares on August 7 for an estimated $293,000, the same day the stock rose 33%. The sale involved exercising stock options followed by an immediate open-market disposition.
Why it matters — DOCS watchers would care because insider selling on a day of a large stock jump can signal director sentiment about the company's valuation.
A Doximity officer's latest insider transaction involved exercising options and disposing shares valued at $140,400 at $24.84 per share. The activity combined a Rule 10b5-1 trading plan sale to cover tax obligations and issuer-withheld shares tied to restricted stock unit vesting.
Why it matters — DOCS watchers would care because insider option exercises and tax-related share dispositions can signal how executives are managing their holdings in the company.
Doximity recently granted its President 150,000 stock options, as reported in a filing. The filing also notes that a disposition of shares totaling about $111,154 in value (based on the August 15 execution price) reduced the insider's direct equity holdings by roughly 8%.
Why it matters — DOCS watchers would care because insider option grants and share dispositions can signal how leadership views the company's equity and their own stake.
Doximity's new CFO filed his first Form 4, disclosing a disposition of 15,311 shares valued at approximately $380,000 based on a weighted average price of $24.80 per share. The transaction reduced his direct holdings by 3% following an underlying vesting event.
Why it matters — A DOCS watcher would care because it is the new CFO's first Form 4 filing, offering insight into insider shareholding activity around a vesting event.
Doximity's co-founder and CEO disposed of 8,505 shares for approximately $211,000 based on transaction-date pricing, as disclosed in a Form 4 filing. The transaction represented just 0.3% of the executive's direct equity holdings.
Why it matters — A DOCS watcher would care because insider selling, even of a small portion of holdings, can draw scrutiny from investors monitoring executive activity.
The 21 Wall Street analysts covering Doximity, Inc. have a median 12-month price target of $28, with estimates ranging from $18 to $47. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 21 analysts covering Doximity, Inc., 9 rate it a Buy, 10 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Doximity, Inc. 61 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Doximity, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).
No one can know that. What the data says: the median 12-month target from 21 analysts implies +10.6% from the last close, and Ticker Nerd's factor model ranks Doximity, Inc. 61 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Doximity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DOCS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $47 over the next 12 months.
Doximity, Inc. returned -60.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Doximity Inc. is a healthcare technology company that operates a digital platform for medical professionals in the United States.
The most recent item we track (The Motley Fool, 18 Aug 2026): "A Doximity Director Moved 7,500 Shares the Day the Stock Popped 33%. Here's What to Know". A Doximity director, Cabral, sold 7,500 shares on August 7 for an estimated $293,000, the same day the stock rose 33%. The sale involved exercising stock options followed by an immediate open-market disposition.
Doximity Inc. is a healthcare technology company that operates a digital platform for medical professionals in the United States. The company’s network connects verified clinicians across specialties and care settings, giving them tools for secure communication, collaboration, and professional networking. Its platform supports virtual patient visits, access to medical news and research, clinical coordination, and career management features designed for physicians, nurse practitioners, physician assistants, and medical students. Doximity also offers cloud-based workflow tools that help streamline documentation, on-call scheduling, and administrative tasks in clinical environments. The company plays a significant role in the U.S. healthcare ecosystem by helping medical professionals communicate more efficiently and access purpose-built digital services tailored to their daily work.
CEO Mr. Jeffrey A. Tangney · 880 employees · United States · https://www.doximity.com